You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
Subdue the cytokine storm
in primary HLH1,2
Target interferon gamma (IFNγ) with Gamifant, the first and only FDA-approved treatment for
primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive
disease or intolerance to conventional therapy.1,3
Preclinical data suggest that the cytokine IFNγ plays a central and upstream role in the pathogenesis of
primary HLH. A massive overexpression of IFNγ leads directly to downstream
hypercytokinemia and hyperinflammation.1,4,5
Gamifant binds to soluble and receptor-bound forms of IFNγ. Binding to IFNγ neutralizes
its activity, blocking its intracellular signaling to inhibit macrophage activation and the
downstream release of proinflammatory cytokines.1,2,6,7
Depending on patient response, Gamifant can be incrementally titrated upward or downward.
Similarly, the concomitant dose of dexamethasone may be tapered from the original starting dose
according to the judgment of the treating physician.1
Gamifant yielded a 63% overall response rate (ORR) in patients
with refractory, recurrent, or progressive disease or intolerance to conventional therapy.
Seventy percent of patients proceeded to transplant.1